AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30852915 — intervention group
Group type: COMPARATOR
Intervention: 0.5% carboxymethylcellulose (group 2)
Number of subjects: 30
Study 31345677 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple target vegetables (3 vegetables)
Number of subjects: 32
Study 31345677 — intervention group
Group type: COMPARATOR
Intervention: Single target vegetable (1 vegetable)
Number of subjects: 32
Study 31345677 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no change in eating habits)
Number of subjects: 32
Study 31345677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinner meal intake
Number of subjects: 32
Study 27920261 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS combined with sensory cueing
Number of subjects: 60
Study 27920261 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS alone
Number of subjects: 60
Study 27920261 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 60
Study 25662596 — intervention group
Group type: EXPERIMENTAL
Intervention: VCB regimen (cisplatin 80 mg/m², oral vinorelbine 60 mg/m², and bevacizumab 15 mg/kg) followed by DGB regimen (docetaxel 75 mg/m², gemcitabine 1100 mg/m², and bevacizumab 15 mg/kg)
Number of subjects: 77
Study 25662596 — intervention group
Group type: COMPARATOR
Intervention: DCB regimen (cisplatin 80 mg/m², docetaxel 75 mg/m², and bevacizumab 15 mg/kg)
Number of subjects: 77
Study 25662596 — intervention group
Group type: EXPERIMENTAL
Intervention: VCB regimen
Number of subjects: 77
Study 25662596 — intervention group
Group type: COMPARATOR
Intervention: DCB regimen
Number of subjects: 77
Study 25662596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 77
Study 23799908 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 50 mg twice daily for 4 weeks, then 100 mg twice daily for 8 weeks
Number of subjects: 52
Study 23799908 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil
Number of subjects: 52
Study 23799908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22938690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannose-binding lectin deficiency (MBL levels ≤ 500 ng/ml)
Number of subjects: 246
Study 22938690 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cystatin C increase of ≥ 10%
Number of subjects: 246
Study 22938690 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine-based CIN
Number of subjects: 246
Study 22938690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C-based CIN
Number of subjects: 246
Study 19633794 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 0
Study 19633794 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17668527 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5%/clindamycin 1% gel as monotherapy
Number of subjects: 0
Study 17668527 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 5%/clindamycin 1% gel in combination with adapalene gel
Number of subjects: 0
Study 17668527 — intervention group
Group type: COMPARATOR
Intervention: Adapalene gel monotherapy
Number of subjects: 0
Study 15496273 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization
Number of subjects: 0
Study 15496273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines in development for mobilization
Number of subjects: 0
Study 10773555 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart transplant recipients
Number of subjects: 75
Study 10773555 — intervention group
Group type: COMPARATOR
Intervention: Heart transplant candidates
Number of subjects: 75
Study 10773555 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 75
Study 8921927 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized diet with adjusted energy intake, increased fish meals and antioxidants
Number of subjects: 109
Study 8921927 — intervention group
Group type: COMPARATOR
Intervention: Standard care without specialized diet
Number of subjects: 109
Study 1316721 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupon offer
Number of subjects: 2109
Study 1316721 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral reminder letter
Number of subjects: 2109
Study 1316721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2109
Study 1316721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-counseling coupon offer
Number of subjects: 2109
Study 1316721 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay-counseling reminder letter
Number of subjects: 2109
Study 4035294 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine
Number of subjects: 20
Study 4035294 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30308004 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional aerobic and resistance exercise
Number of subjects: 18
Study 30308004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel exercise
Number of subjects: 18
Study 30308004 — intervention group
Group type: COMPARATOR
Intervention: No-exercise (control group)
Number of subjects: 18
Study 28834483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target systolic blood pressure < 120 mm Hg)
Number of subjects: 9361
Study 28834483 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (target systolic blood pressure < 140 mm Hg)
Number of subjects: 9361
Study 28834483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 9361
Study 28834483 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 9361
Study 28834483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 9361
Study 25183702 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular electrical stimulation combined with auricular acupressure
Number of subjects: 134
Study 25183702 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint stimulation
Number of subjects: 134
Study 22922526 — intervention group
Group type: EXPERIMENTAL
Intervention: High partner influence
Number of subjects: 44
Study 22922526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low partner influence
Number of subjects: 44
Study 21944067 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-molded foot orthosis (FO)
Number of subjects: 16
Study 21944067 — intervention group
Group type: COMPARATOR
Intervention: Balanced traditional orthosis
Number of subjects: 16
Study 21944067 — intervention group
Group type: COMPARATOR
Intervention: Full-contact orthosis
Number of subjects: 16
Study 18324527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato extract (45 mg lycopene/day)
Number of subjects: 32
Study 18324527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (45 mg lycopene/day)
Number of subjects: 32
Study 18324527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17163232 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg once daily (regimen A)
Number of subjects: 24
Study 17163232 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily (regimen B)
Number of subjects: 24
Study 17163232 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg once daily plus hydrochlorothiazide 25 mg once daily (regimen C)
Number of subjects: 24
Study 14604159 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of anti-epileptic drug therapy (AED)
Number of subjects: 115
Study 14604159 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of anti-epileptic drug therapy (AED)
Number of subjects: 115
Study 14604159 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal CT prior to AED withdrawal
Number of subjects: 115
Study 14604159 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal EEG prior to AED withdrawal
Number of subjects: 115
Study 14604159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of persistent/calcified CT lesion and abnormal EEG prior to AED withdrawal
Number of subjects: 115
Study 14604159 — intervention group
Group type: COMPARATOR
Intervention: 1 vs. 2 years of AED therapy
Number of subjects: 115
Study 10985512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 500 mcg intramuscularly
Number of subjects: 20
Study 10985512 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline 1 mL intramuscularly
Number of subjects: 20
Study 8874574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after induction of general anaesthesia
Number of subjects: 50
Study 8874574 — intervention group
Group type: COMPARATOR
Intervention: Post-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after surgery
Number of subjects: 50
Study 8874574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received paracetamol 15-20 mg/kg rectally when admitted to the recovery ward
Number of subjects: 50
Study 8874574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 1393167 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape-recorded consultations
Number of subjects: 0
Study 1393167 — intervention group
Group type: COMPARATOR
Intervention: Non tape-recorded consultations
Number of subjects: 0
Study 4001842 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of unconjugated chenodeoxycholic acid (CDA)
Number of subjects: 0
Study 4001842 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction
Number of subjects: 0
Study 30285499 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Advocate (PA) intervention, which includes meeting with patients before medical visits, attending appointments, and reviewing provider instructions.
Number of subjects: 24
Study 30285499 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider focus groups and interviews (qualitative analysis).
Number of subjects: 24
Study 29732624 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and Rehabilitation 2: Short Version for Adults (R&R2)
Number of subjects: 101
Study 29732624 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 101
Study 25851059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% acetic acid
Number of subjects: 32
Study 25851059 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 32
Study 24226808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hs-TnI)
Number of subjects: 14821
Study 24226808 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 14821
Study 24226808 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14821
Study 22622852 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone (20 mg)
Number of subjects: 239
Study 22622852 — intervention group
Group type: COMPARATOR
Intervention: Intravenous piritramide PCA (2 mg piritramide/ml 0.9 % saline)
Number of subjects: 239
Study 22622852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (oral oxycodone and PCA)
Number of subjects: 239
Study 20397131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 12
Study 20397131 — intervention group
Group type: COMPARATOR
Intervention: No restricted diffusion on DWI
Number of subjects: 12
Study 18062829 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg, 200 microg, or 300 microg Se as Se-enriched yeast)
Number of subjects: 105
Study 18062829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 16027558 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 68
Study 16027558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 14674116 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador QuS administered s.c. twice a week for 3 months
Number of subjects: 96
Study 14674116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intron A administered twice a week in cervical injections for 3 months
Number of subjects: 96
Study 14674116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study 10757101 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured medical advice during ICU hospitalization and follow-up in the second, third, and fourth week
Number of subjects: 90
Study 10757101 — intervention group
Group type: COMPARATOR
Intervention: Ordinary anti-tobacco advice
Number of subjects: 90
Study 8186159 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (ifosfamide, cisplatin, vinblastine)
Number of subjects: 136
Study 8186159 — intervention group
Group type: COMPARATOR
Intervention: PV (cisplatin, vinblastine)
Number of subjects: 136
Study 2451412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxendolone + Bunazosin
Number of subjects: 0
Study 2451412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunazosin
Number of subjects: 0
Study 2451412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxendolone
Number of subjects: 0
Study 29664106 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus therapeutic exercise
Number of subjects: 60
Study 29664106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate plus therapeutic exercise
Number of subjects: 60
Study 29664106 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercise alone (control group with saline injection)
Number of subjects: 60
Study 29664106 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Component Summary‐36 and Mental Component Summary‐36 scores
Number of subjects: 60
Study 29664106 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline injection) vs Hyaluronate
Number of subjects: 60
Study 29664106 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging and X-ray images
Number of subjects: 60
Study 26811535 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg per day
Number of subjects: 396
Study 26811535 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50 mg per day
Number of subjects: 396
Study 26409883 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary programme (MD)
Number of subjects: 203
Study 26409883 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 203
Study 26409883 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 203
Study 23488643 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA
Number of subjects: 7
Study 23488643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 21323255 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer review intervention group
Number of subjects: 47
Study 21323255 — intervention group
Group type: COMPARATOR
Intervention: Control group (self-assessment)
Number of subjects: 47
Study 19815828 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster patients
Number of subjects: 7760
Study 19815828 — intervention group
Group type: COMPARATOR
Intervention: Comparison cohort
Number of subjects: 7760
Study 19815828 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster ophthalmicus
Number of subjects: 7760
Study 17988824 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-midazolam
Number of subjects: 19
Study 17988824 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-midazolam
Number of subjects: 19
Study 15555291 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine combined with TACE
Number of subjects: 49
Study 15555291 — intervention group
Group type: COMPARATOR
Intervention: TACE only
Number of subjects: 49
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 992
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription from a gynecologist
Number of subjects: 992
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammogram a year prior to initiation
Number of subjects: 992
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOI) or selective serotonin reuptake inhibitors (SSRI) antidepressants 3 months prior to initiation
Number of subjects: 992
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment in the health plan for less than 3 years
Number of subjects: 992
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of cohort entry (1994)
Number of subjects: 992
Study 11576818 — intervention group
Group type: EXPERIMENTAL
Intervention: Year of cohort entry (1995)
Number of subjects: 992
Study 9046380 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol cues
Number of subjects: 30
Study 9046380 — intervention group
Group type: COMPARATOR
Intervention: Control cues
Number of subjects: 30
Study 8582196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen-based hormone replacement therapy
Number of subjects: 0
Study 8582196 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen
Number of subjects: 0
Study 8582196 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogens
Number of subjects: 0
Study 8582196 — intervention group
Group type: EXPERIMENTAL
Intervention: Certain progesterone metabolites
Number of subjects: 0
Study 2570798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 25 mg twice daily
Number of subjects: 16
Study 2570798 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 16
Study 71209 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP (cyclophosphamide, vincristine, and prednisone)
Number of subjects: 57
Study 71209 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP (adriamycin, bleomycin, and prednisone)
Number of subjects: 57
Study 71209 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP (after crossover for progression or relapse)
Number of subjects: 57
Study 71209 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP (after crossover for progression or relapse)
Number of subjects: 57
Study 71209 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP and ABP (sequentially alternated in subsequent study)
Number of subjects: 57
Study 31576607 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (20% of daily energy for 16 weeks)
Number of subjects: 28
Study 31576607 — intervention group
Group type: COMPARATOR
Intervention: Calorie-matched snack (control group)
Number of subjects: 28
Study 28167383 — intervention group
Group type: EXPERIMENTAL
Intervention: Group presence
Number of subjects: 203
Study 28167383 — intervention group
Group type: EXPERIMENTAL
Intervention: Category labels
Number of subjects: 203
Study 28167383 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic statements
Number of subjects: 203
Study 28167383 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 203
Study 26312522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing guidance protocol about bed bath
Number of subjects: 120
Study 26312522 — intervention group
Group type: COMPARATOR
Intervention: Routine information from the unit
Number of subjects: 120
Study 23949731 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF/ICSI with PGS
Number of subjects: 113
Study 23949731 — intervention group
Group type: COMPARATOR
Intervention: IVF/ICSI without PGS (control)
Number of subjects: 113
Study 22097978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile normothermia CPB (PNCPB)
Number of subjects: 60
Study 22097978 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile normothermia CPB (NNCPB)
Number of subjects: 60
Study 22097978 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile moderate hypothermia CPB (NHCPB)
Number of subjects: 60
Study 22097978 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile moderate hypothermia CPB (PHCPB)
Number of subjects: 60
Study 18753185 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI), n=81
Number of subjects: 100
Study 18753185 — intervention group
Group type: COMPARATOR
Intervention: Histamine-2 receptor antagonist (H2RA), n=19
Number of subjects: 100
Study 16670069 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent/detergent (SD) plasma
Number of subjects: 17
Study 15799926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless aortic valve replacement (Freestyle)
Number of subjects: 16
Study 15799926 — intervention group
Group type: COMPARATOR
Intervention: Stented aortic valve replacement (Mosaic)
Number of subjects: 16
Study 11010599 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiratory effort (targeted peak inhalation flow 30 L/min)
Number of subjects: 10
Study 11010599 — intervention group
Group type: COMPARATOR
Intervention: Submaximal inspiratory effort (targeted peak inhalation flow 15 L/min)
Number of subjects: 10
Study 9283989 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg once daily
Number of subjects: 84
Study 9283989 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg once daily
Number of subjects: 84
Study 8356856 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (3.0 micrograms/kg)
Number of subjects: 20
Study 8356856 — intervention group
Group type: COMPARATOR
Intervention: Morphine (100 micrograms/kg)
Number of subjects: 20
Study 3322310 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-palmitoyl-(+)‐catechin at a dose of 1500 mg daily (500 mg t.d.s.) for 3 months
Number of subjects: 0
Study 3322310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3322310 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-palmitoyl-(+)‐catechin
Number of subjects: 0
Study 30012380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n=120)
Number of subjects: 441
Study 30012380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n=100)
Number of subjects: 441
Study 30012380 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (n=121)
Number of subjects: 441
Study 30012380 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (n=100)
Number of subjects: 441
Study 30012380 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (n=120) and (n=100)
Number of subjects: 441
Study 30012380 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (n=121) and (n=100)
Number of subjects: 441
Study 27618810 — intervention group
Group type: EXPERIMENTAL
Intervention: Family health history (FHH) risk assessment tool
Number of subjects: 150